The Human Papillomavirus (HPV) is a group of viruses that can infect the genital area, mouth, and throat. Some strains of HPV have the potential to cause various types of cancers, including cervical cancer. Medical researchers have developed vaccines to address the spread of this virus and its associated risks. These vaccines have proven to be effective in preventing HPV infection and related complications.
What are the Vaccines for Human Papillomavirus?
There are mainly three Human Papillomavirus (HPV) infection vaccines available: Gardasil 9 (9vHPV), Gardasil (4vHPV), and Cervarix (2vHPV). Regulatory authorities such as the US Food and Drug Administration (FDA) have licensed these vaccines for their proven safety and effectiveness in preventing HPV infections. The vaccines work by stimulating the system to produce antibodies that target the types of HPV, thereby reducing the risk of infection and associated diseases, including various cancers.
Gardasil 9 is a vaccine that protects from nine types of HPV, including high-risk types such as HPV 16 and 18, which can potentially lead to cancers. It is authorised for both males and females and administered through several doses.
Gardasil vaccine targets four types of HPV, including types 16 and 18. It was one of the first vaccines formulated for preventing HPV. This vaccine is also approved for use in both males and females and is administered through a series of doses.
The Cervarix vaccine, also known as 2vHPV, offers protection from two types of HPV: types 16 and 18. Its primary purpose is to prevent cervical cancer, and it is usually administered in a series of doses.